Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review (Q34726169)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

systematic review

1 reference

based on heuristic

inferred from title

1

object named as

Colleen Wegzyn

0 references

Kristina Unnebrink

5

object named as

Kristina Unnebrink

0 references

7

object named as

Doris Makari

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Colleen Wegzyn

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Lim Kai Toh

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Gerard Notario

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sophie Biguenet

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Kristina Unnebrink

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Caroline Park

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Michael Norton

8

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

9 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Infectious diseases and therapy

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

133-158

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Challenges and opportunities for respiratory syncytial virus vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Clinical and epidemiologic features of respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Vaccination against RSV: is maternal vaccination a good alternative to other approaches?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory syncytial virus: current progress in vaccine development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Risk factors for severe respiratory syncytial virus lower respiratory tract infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Use of palivizumab in Germany: data from 2002-2007.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory syncytial virus infection in children.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Prevention of respiratory syncytial virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory Morbidity in Late Preterm Births

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Health economics and RSV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Outcomes of late-preterm infants: a retrospective, single-center, Canadian study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269625

7 July 2018

Infectious disease hospitalizations among infants in the United States.

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

CARESS: the Canadian registry of palivizumab.

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Guidelines for the use of palivizumab in infants and young children with congenital heart disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Morbidity and Discharge Timing of Late Preterm Newborns

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40121-014-0046-6

21 January 2018

[Recommendations for the prevention of respiratory syncytial virus infection]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25297809

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25297809

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late preterm infants: birth outcomes and health care utilization in the first year

1 reference

https://pubmed.ncbi.nlm.nih.gov/25297809

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25297809

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40121-014-0046-6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34726169&oldid=2196983356"